NCT06753747View on ClinicalTrials.gov

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Esophagus Cancer
Interventions
DRUG

Palbociclib

Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.

DRUG

Afatinib(30mg)

Afatinib will be administered orally at a dose of 30 mg once daily (QD) in each 4-week cycle.

DRUG

Afatinib(40mg)

Afatinib will be administered orally at a dose of 40 mg once daily (QD) in each 4-week cycle.

DRUG

Afatinib(RP2D)

In the Phase 2 study, the recommended Phase 2 dose (RP2D) of Afatinib, determined during the Phase 1b portion, will be utilized.

Trial Locations (1)

610041

West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER